CoChat

Portable light therapy in the treatment of unipolar non-seasonal major depressive disorder: study protocol for the LUMIDEP randomised controlled trial

Cosker, Eve, Moulard, Marie, Schmitt, Samuel, Angioi-Duprez, Karine, Baumann, Cédric, Laprévote, Vincent, Schwan, Raymund, Schwitzer, Thomas · 2021 · BMJ Open
Cited by 7

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Introduction: Major depressive disorder (MDD) affects more than 264 million people worldwide and is associated with an impaired quality of life as well as a higher risk of mortality. Current routine treatments demonstrate limited effectiveness. Light therapy (LT) on its own or in combination with antidepressant treatments could be an effective treatment, but the use of conventional LT devices use is restrictive. Portable LT devices allow patients to continue with their day-to-day activities and therefore encourage better treatment compliance. They have not been evaluated in MDD. Methods and analysis: The study is a single-centre, double-blind, randomised controlled trial assessing the efficacy of LT delivered via a portable device in addition to usual care (medical care and drug treatment) for inpatients and outpatients with unipolar non-seasonal MDD. Over the course of 8 weeks, patients use the device daily for 30 min at medium intensity as soon as possible after waking up and preferably between 07:00 and 09:00. All patients continue their usual care with their referring physician. N=50 patients with MDD are included. The primary outcome measure is depressive symptom severity assessed using the Montgomery-Åsberg Depression Rating Scale between baseline and the eighth week. Secondary outcome measures are sleep quality assessed using the Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale and anxiety level assessed on the Hamilton Anxiety Rating Scale, between baseline and week 8. Further parameters relating to cognitive function are measured at baseline and after the intervention. An ancillary study aims to evaluate the impact of MDD on the retina and to follow its progression. Main limitations include risk of discontinuation or non-adherence and bias in patient selection. Ethics and dissemination: The study protocol was approved by Ile de France X’s Ethics Committee (protocol number 34–2018). Findings will be published in peer-reviewed journals. Trial registration number: NCT03685942 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2021-049331

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 40

  1. 10.1016/S0140-6736(18)32279-7 · DOI · Paper page
  2. 10.3109/10673229.2011.630828 · DOI · Paper page
  3. 10.1503/cmaj.170125 · DOI · Paper page
  4. 10.2165/00023210-200721110-00003 · DOI
  5. Cosker, 2020, New insights on the role of the retina in diagnostic and therapeutic strategies in major depressive disorder, Neurosci Biobehav Rev, 113, 262, 10.1016/j.neubiorev.2020.03.006 · DOI
  6. 10.1155/2017/7407241 · DOI · Paper page
  7. Pévet, 2014, The internal time-giver role of melatonin. A key for our health, Rev Neurol, 170, 646, 10.1016/j.neurol.2014.05.008 · DOI
  8. 10.1080/01612840591008410 · DOI · Paper page
  9. 10.1111/j.1600-0447.2005.00574.x · DOI · Paper page
  10. Prasko, 2002, Bright light therapy and/or imipramine for inpatients with recurrent non-seasonal depression, Neuro Endocrinol Lett, 23, 109
  11. 10.1017/S0033291706008105 · DOI · Paper page
  12. Langevin, 2014, Évaluation préliminaire de l’efficacité de la Luminette® chez des adolescents atteints du syndrome de retard de phase du sommeil (SRPS) : essai randomisé en simple insu et contrôlé par placebo, Médecine du Sommeil, 11, 91, 10.1016/j.msom.2014.03.003 · DOI
  13. Slama, 2015, Afternoon nap and bright light exposure improve cognitive flexibility post lunch, PLoS One, 10, 10.1371/journal.pone.0125359 · DOI · Paper page
  14. 10.1016/j.preteyeres.2014.06.003 · DOI · Paper page
  15. 10.1016/j.biopsych.2012.11.024 · DOI
  16. 10.1038/nrneurol.2012.227 · DOI · Paper page
  17. Schwitzer, 2015, The emerging field of retinal electrophysiological measurements in psychiatric research: a review of the findings and the perspectives in major depressive disorder, J Psychiatr Res, 70, 113, 10.1016/j.jpsychires.2015.09.003 · DOI
  18. 10.1192/bjp.bp.111.100560 · DOI
  19. 10.1016/j.jad.2011.07.013 · DOI
  20. 10.1007/s10633-017-9621-y · DOI · Paper page
  21. Sheehan, 1998, The Mini-International neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J Clin Psychiatry, 59 Suppl 20, 22
  22. 10.1192/bjp.134.4.382 · DOI · Paper page
  23. 10.1016/0165-1781(89)90047-4 · DOI · Paper page
  24. 10.1093/sleep/14.6.540 · DOI · Paper page
  25. 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
  26. 10.1111/j.1532-5415.2005.53221.x · DOI · Paper page
  27. Rieu, 2006, [French adaptation of the Hopkins Verbal Learning Test], Rev Neurol, 162, 721, 10.1016/S0035-3787(06)75069-X · DOI
  28. 10.1037/h0054651 · DOI · Paper page
  29. 10.1016/S0887-6177(03)00039-8 · DOI · Paper page
  30. 10.1080/13803395.2010.516743 · DOI
  31. 10.1111/j.1360-0443.1991.tb01879.x · DOI · Paper page
  32. 10.3109/07420528.2013.833935 · DOI · Paper page
  33. Giedd, 1998, Case series: pediatric seasonal affective disorder. A follow-up report, J Am Acad Child Adolesc Psychiatry, 37, 218, 10.1097/00004583-199802000-00015 · DOI
  34. Kirschbaum-Lesch, 2018, Feasibility and efficacy of bright light therapy in depressed adolescent inpatients, Z Kinder Jugendpsychiatr Psychother, 46, 423, 10.1024/1422-4917/a000603 · DOI
  35. 10.1002/gps.1125 · DOI · Paper page
  36. Meesters, 2016, The effects of low-intensity narrow-band blue-light treatment compared to bright white-light treatment in sub-syndromal seasonal affective disorder, BMC Psychiatry, 16, 10.1186/s12888-016-0729-5 · DOI
  37. Kalenderoglu, 2016, Optic coherence tomography shows inflammation and degeneration in major depressive disorder patients correlated with disease severity, J Affect Disord, 204, 159, 10.1016/j.jad.2016.06.039 · DOI
  38. Yıldız, 2016, Duration of the depressive episode is correlated with ganglion cell inner plexifrom layer and nasal retinal fiber layer thicknesses: optical coherence tomography findings in major depression, Psychiatry Res Neuroimaging, 251, 60, 10.1016/j.pscychresns.2016.04.011 · DOI
  39. Schönfeldt-Lecuona, 2018, Retinal changes in patients with major depressive disorder - A controlled optical coherence tomography study, J Affect Disord, 227, 665, 10.1016/j.jad.2017.11.077 · DOI
  40. Sönmez, 2017, Retinal nerve fiber layer thickness measurement by spectral-domain optical coherence tomography in patients with major depressive disorder, Noro Psikiyatr Ars, 54, 62, 10.5152/npa.2015.10115 · DOI

Cited by

  • Light therapy in medicine: where do we stand?

    Oyama, Y., Witowski, A., Adamzik, M., Bartels, K., & de la Garza Eckle, T. (2026) · Annals of Translational Medicine · doi:10.21037/atm-2026-0041

    “Additionally, portable light therapy devices have been developed to improve treatment accessibility and compliance, allowing patients to integrate therapy into their daily routines (103).”

See all 7

Metadata

Authors
Cosker, E., Moulard, M., Schmitt, S., Angioi-Duprez, K., Baumann, C., Laprévote, V., Schwan, R., & Schwitzer, T.
Affiliations
  • Pôle Hospitalo-Universitaire De Psychiatrie d"Adultes et d"Addictologie Du Grand Nancy, Centre Psychothérapique de Nancy, Laxou, Lorraine, France
  • Département d’Ophtalmologie, Centre Hospitalier Universitaire de Nancy, Nancy, France
  • Unité ESPRI-BioBase, Platforme PARC, CHRU de Nancy, Nancy, Lorraine, France
Venue
BMJ Open
Publisher
BMJ
Published
2021-07
Volume
11
Issue
7
Pages
e049331
ISSN
2044-6055
Cited by
7
References
16
Language
en
Funders
  • LUCIMED SA (N/A)
  • Centre Psychothérapique de Nancy, Laxou, France (N/A)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.